{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:45Z","timestamp":1792784985813,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The JSPS KAKENHI","award":["JP17K11265"],"award-info":[{"award-number":["JP17K11265"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 2018 International Federation of Gynecology and Obstetrics (FIGO) revision to the staging criteria for uterine cervical cancer adopted pathological staging for patients who underwent surgery. We investigated the correlation between clinicopathological factors and prognosis in patients with high-risk factors in accordance with the FIGO 2018 staging criteria by analyzing a real-world database of 6,192 patients who underwent radical hysterectomy at 116 institutions belonging to the Japan Gynecologic Oncology Group. A total of 1,392 patients were categorized into the high-risk group. Non-squamous cell carcinoma histology, regional lymph node metastasis, pT2 classification, and ovarian metastasis were identified as independent risk factors for mortality. Based on pathological findings, 313, 1003, and 76 patients were re-classified into FIGO 2018 stages IIB, IIIC1p, and IIIC2p, respectively. Patients with stage IIIC2p disease showed worse prognoses than those with stage IIB or IIIC1p disease. In patients with stage IIIC1p disease, overall survival was significantly better if their tumors were localized in the uterine cervix, except for single lymph node metastasis, with a 5-year overall survival rate of 91.8%. This study clarified the heterogeneity of the high-risk group and provided insights into the feasibility of upfront radical hysterectomy for a limited number of patients harboring high-risk factors.<\/jats:p>","DOI":"10.1038\/s41598-023-39014-8","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T10:02:27Z","timestamp":1690279347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Surgically treated cervical cancer in a high-risk group in the era of the 2018 FIGO staging schema: a nationwide study"],"prefix":"10.1038","volume":"13","author":[{"given":"Shogo","family":"Shigeta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zen","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"issue":"41","key":"39014_CR1","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1016\/j.vaccine.2022.08.020","volume":"40","author":"HJ Prudden","year":"2022","unstructured":"Prudden, H. J. et al. Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World health organization consultations, October 2021\u2013March 2022. Vaccine 40(41), 5843\u20135855 (2022).","journal-title":"Vaccine"},{"issue":"8","key":"39014_CR2","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","volume":"10","author":"L Bruni","year":"2022","unstructured":"Bruni, L. et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: A review and synthetic analysis. Lancet Glob. Health. 10(8), e1115\u2013e1127 (2022).","journal-title":"Lancet Glob. Health."},{"key":"39014_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106399","volume":"144","author":"L Bruni","year":"2021","unstructured":"Bruni, L. et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019. Prev. Med. 144, 106399 (2021).","journal-title":"Prev. Med."},{"issue":"2","key":"39014_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-059968","volume":"12","author":"D Machalek","year":"2022","unstructured":"Machalek, D. et al. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: Study protocol and rationale for a pragmatic before-after design. BMJ Open 12(2), e059968 (2022).","journal-title":"BMJ Open"},{"issue":"3","key":"39014_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"39014_CR6","unstructured":"Cancer Information Service, National Cancer Center, Japan. Cancer Statistics (Vital Statistics of Japan, Ministry of Health, Labour and Welfare)."},{"issue":"1","key":"39014_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijgo.12749","volume":"145","author":"N Bhatla","year":"2019","unstructured":"Bhatla, N. et al. Revised FIGO staging for carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet. 145(1), 129\u2013135 (2019).","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"9077","key":"39014_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(97)02250-2","volume":"350","author":"F Landoni","year":"1997","unstructured":"Landoni, F. et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350(9077), 535\u2013540 (1997).","journal-title":"Lancet"},{"key":"39014_CR9","unstructured":"National Comprehensive Cancer Network. Cervical Cancer (Version 1.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf (2022)."},{"key":"39014_CR10","unstructured":"Japan Society of Gynecologic Oncology. Guidelines for treatment of uterine cervical cancer; Japan Society of Gynecologic Oncology (JSGO) 2022 edition. (In Japanese)"},{"issue":"3","key":"39014_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/jog.15112","volume":"48","author":"M Shimada","year":"2022","unstructured":"Shimada, M. et al. Rethinking the significance of surgery for uterine cervical cancer. J. Obstet. Gynaecol. Res. 48(3), 576\u2013586 (2022).","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"7","key":"39014_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IGC.0000000000000202","volume":"24","author":"M Mikami","year":"2014","unstructured":"Mikami, M. et al. Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: A survey of the Japanese gynecologic oncology group. Int. J. Gynecol. Cancer. 24(7), 1333\u20131340 (2014).","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"1","key":"39014_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ygyno.2020.07.023","volume":"159","author":"S Shigeta","year":"2020","unstructured":"Shigeta, S. et al. Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project. Gynecol. Oncol. 159(1), 248\u2013255 (2020).","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"39014_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4307","volume":"3","author":"N Sakuragi","year":"2020","unstructured":"Sakuragi, N. et al. Oncological outcomes after Okabayashi-Kobayashi radical hysterectomy for early and locally advanced cervical cancer. JAMA Netw. Open. 3(5), e204307 (2020).","journal-title":"JAMA Netw. Open."},{"issue":"8","key":"39014_CR15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"WA Peters","year":"2000","unstructured":"Peters, W. A. et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18(8), 1606\u20131613 (2000).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"39014_CR16","first-page":"CD005342","volume":"11","author":"FS Falcetta","year":"2016","unstructured":"Falcetta, F. S. et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst. Rev. 11(11), CD005342 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl_4","key":"39014_CR17","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","volume":"28","author":"C Marth","year":"2017","unstructured":"Marth, C. et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl_4), iv72\u2013iv83 (2017).","journal-title":"Ann Oncol"},{"issue":"2","key":"39014_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 105(2), 103\u2013104 (2009).","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"11","key":"39014_CR19","first-page":"1289","volume":"52","author":"Y Shibuya","year":"2022","unstructured":"Shibuya, Y. et al. Prognostic factors of 2018 FIGO stage IB-IIA cervical cancer with absence of high\/ intermediate surgical-pathological risk factors. Jpn. J. Clin. Oncol. 52(11), 1289\u20131296 (2022).","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"9","key":"39014_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s10147-022-02198-6","volume":"27","author":"S Shigeta","year":"2022","unstructured":"Shigeta, S. et al. Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: A multicenter, retrospective analysis by the Japanese gynecologic oncology group. Int. J. Clin. Oncol. 27(9), 1507\u20131515 (2022).","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"39014_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/gyno.1999.5387","volume":"73","author":"A Sedlis","year":"1999","unstructured":"Sedlis, A. et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A gynecologic oncology group study. Gynecol. Oncol. 73(2), 177\u2013183 (1999).","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"39014_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ygyno.2005.05.026","volume":"99","author":"G Van de Putte","year":"2005","unstructured":"Van de Putte, G., Lie, A. K., Vach, W., Baekelandt, M. & Kristensen, G. B. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol. Oncol. 99(1), 106\u2013112 (2005).","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"39014_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1447-0756.2008.00739.x","volume":"34","author":"M Hosaka","year":"2008","unstructured":"Hosaka, M. et al. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J. Obstet. Gynaecol. Res. 34(4), 552\u2013556 (2008).","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"3","key":"39014_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10147-014-0724-0","volume":"20","author":"I Deura","year":"2015","unstructured":"Deura, I. et al. Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy. Int. J. Clin. Oncol. 20(3), 556\u2013560 (2015).","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"39014_CR25","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2021.32.e44","volume":"32","author":"M Ikeda","year":"2021","unstructured":"Ikeda, M. et al. The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: A report from the Japan society of gynecologic oncology (JSGO) guidelines evaluation committee. J. Gynecol. Oncol. 32(3), e44 (2021).","journal-title":"J. Gynecol. Oncol."},{"issue":"4","key":"39014_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1620\/tjem.255.303","volume":"255","author":"S Miyahara","year":"2021","unstructured":"Miyahara, S. et al. The impact of histological subtype on survival outcome of patients with stage IIB-IVA cervical cancer who received definitive radiotherapy. Tohoku J. Exp. Med. 255(4), 303\u2013313 (2021).","journal-title":"Tohoku J. Exp. Med."},{"issue":"4","key":"39014_CR27","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3892\/mco.2013.112","volume":"1","author":"M Shimada","year":"2013","unstructured":"Shimada, M. et al. Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG\/TGCU intergroup surveillance. Mol. Clin. Oncol. 1(4), 780\u2013784 (2013).","journal-title":"Mol. Clin. Oncol."},{"issue":"1","key":"39014_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2019.01.022","volume":"153","author":"S Nishio","year":"2019","unstructured":"Nishio, S. et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix: An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecol. Oncol. 153(1), 13\u201319 (2019).","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"39014_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/ijgc-2020-002344","volume":"31","author":"A Furusawa","year":"2021","unstructured":"Furusawa, A. et al. A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese gynecologic oncology group study (JGOG1082). Int. J. Gynecol. Cancer 31(4), 623\u2013626 (2021).","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"39014_CR30","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.30793","volume":"141","author":"K Matsuo","year":"2017","unstructured":"Matsuo, K. et al. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation. Int. J. Cancer 141(5), 1042\u20131051 (2017).","journal-title":"Int. J. Cancer"},{"issue":"6","key":"39014_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/cancers12061552","volume":"12","author":"LP Anchora","year":"2020","unstructured":"Anchora, L. P. et al. Should the number of metastatic pelvic lymph nodes be integrated into the 2018 FIGO staging classification of early stage cervical cancer?. Cancers (Basel). 12(6), 1552 (2020).","journal-title":"Cancers (Basel)."},{"key":"39014_CR32","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.2147\/CMAR.S204154","volume":"11","author":"DD Yan","year":"2019","unstructured":"Yan, D. D., Tang, Q., Tu, Y. Q., Chen, J. H. & Lv, X. J. A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p. Cancer Manag. Res. 11, 4223\u20134230 (2019).","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"39014_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","volume":"152","author":"K Matsuo","year":"2019","unstructured":"Matsuo, K., Machida, H., Mandelbaum, R. S., Konishi, I. & Mikami, M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol. Oncol. 152(1), 87\u201393 (2019).","journal-title":"Gynecol. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39014-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T10:06:15Z","timestamp":1690279575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39014-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39014"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39014-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A. received honoraria from Merck Sharp and Dohme and Chugai Pharmaceutical. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12020"}}